James Peach has joined the Precision Medicine Catapult (PMC) as Chief Operating Officer, following three years as Managing Director of the Main Programme of Genomics England.
Having been working in the medical industry for more than 12 years, James brings a huge amount of experience to the PMC. During his time at Genomics England, James oversaw the establishment of the world’s largest whole genome sequencing operation embedded in routine care across the NHS, for patients with rare inherited diseases and cancer. Prior to his role at Genomics England, James was a partner at Syncona – the Wellcome Trust healthcare investment partnership – and set up and led the Cancer Research UK Stratified Medicine Programme, a cancer genetics partnership with AstraZeneca and Pfizer.
James has also been a member of the Department of Health’s Emerging Science and Bioethics Advisory Committee, and the Human Genomics Strategy Group. His early career was in management consulting at McKinsey & Company and Credo.
Dr Belinda Quinn, CEO of PMC said: “We are delighted to welcome James to the Precision Medicine Catapult as COO. His experience, knowledge and understanding of so many key parts of the medical sector will be a major boost to the PMC as we continue to establish ourselves and build our team. Additionally, his guidance will inevitably help us towards our goal of growing the UK to becoming the leading country for precision medicine.”
James Peach added: “I’m looking forward to working with Belinda and the team to ensure that the Precision Medicine Catapult is a success. The UK is a fantastic environment for growing precision medicine businesses and addressing the pressing patient need for advanced diagnostics and targeted therapies, but many challenges remain. The Precision Medicine Catapult is well placed to work with all the stakeholders and accelerate the growth of this vital industry.”